Meridian Bioscience Stock Forecast, Price & News

-0.35 (-1.75 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume263,726 shs
Average Volume607,537 shs
Market Capitalization$851.91 million
P/E Ratio12.13
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Meridian Bioscience logo

About Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products; and sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.03 out of 5 stars

Medical Sector

537th out of 1,352 stocks

Diagnostic Substances Industry

3rd out of 25 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

Is Meridian Bioscience a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Meridian Bioscience?

Wall Street analysts have given Meridian Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Meridian Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Meridian Bioscience?

Meridian Bioscience saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 3,870,000 shares, a decrease of 14.6% from the July 29th total of 4,530,000 shares. Based on an average daily trading volume, of 513,600 shares, the days-to-cover ratio is currently 7.5 days. Approximately 9.0% of the shares of the company are short sold.
View Meridian Bioscience's Short Interest

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Meridian Bioscience

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings data on Thursday, August, 5th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.09. The business had revenue of $63.51 million for the quarter, compared to the consensus estimate of $73.12 million. Meridian Bioscience had a trailing twelve-month return on equity of 24.58% and a net margin of 23.29%.
View Meridian Bioscience's earnings history

How has Meridian Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VIVO shares have increased by 205.6% and is now trading at $19.65.
View which stocks have been most impacted by COVID-19

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY 2021 earnings guidance on Friday, September, 3rd. The company provided earnings per share (EPS) guidance of $1.610-$1.670 for the period, compared to the Thomson Reuters consensus estimate of $1.720. The company issued revenue guidance of $308 million-$314 million, compared to the consensus revenue estimate of $326.05 million.

What price target have analysts set for VIVO?

2 brokers have issued twelve-month price objectives for Meridian Bioscience's shares. Their forecasts range from $27.00 to $34.00. On average, they expect Meridian Bioscience's share price to reach $30.50 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Meridian Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • John Patrick Kenny, Chief Executive Officer & Executive Director
  • Bryan T. Baldasare, CFO, Secretary, Treasurer & Executive VP
  • Lourdes Weltzien, Executive Vice President-Life Science
  • Tony Serafini-Lamanna, Executive Vice President-Diagnostics
  • Charles Wood, VP-Corporate Strategy, Business Development & IR

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience CEO Jack Kenny on Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.11%), Vanguard Group Inc. (11.71%), Renaissance Technologies LLC (4.32%), Dimensional Fund Advisors LP (4.20%), State Street Corp (4.14%) and Fuller & Thaler Asset Management Inc. (3.91%). Company insiders that own Meridian Bioscience stock include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mccune Jr Rice, John Mcilwraith and John P Kenny.
View institutional ownership trends for Meridian Bioscience

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Renaissance Technologies LLC, Prudential Financial Inc., M&G Investment Management Ltd., Wells Fargo & Company MN, and Parametric Portfolio Associates LLC. Company insiders that have sold Meridian Bioscience company stock in the last year include Bryan T Baldasare, John Mccune Jr Rice, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fort Washington Investment Advisors Inc. OH, Kempen Capital Management N.V., Acuitas Investments LLC, State Street Corp, Systematic Financial Management LP, Millennium Management LLC, and Fuller & Thaler Asset Management Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience
or or view top insider-buying stocks.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $19.65.

How much money does Meridian Bioscience make?

Meridian Bioscience has a market capitalization of $851.91 million and generates $253.67 million in revenue each year. The company earns $46.19 million in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does Meridian Bioscience have?

Meridian Bioscience employs 750 workers across the globe.

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.

When was Meridian Bioscience founded?

Meridian Bioscience was founded in 1977.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is

Where are Meridian Bioscience's headquarters?

Meridian Bioscience is headquartered at 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at (513) 271-3700 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.